MediciNova Inc
Closed
SectorHealthcare
1.78 4.71
Overview
Share price change
24h
Min
1.78
Max
1.8
Income | -2.3B -2.3B |
|---|---|
Sales | 271K 458K |
EPS | -0.05 |
Profit margin | -504,786.678 |
Employees | 6 |
EBITDA | 5.1K -2.5M |
Next Earnings | 10 Nov 2026 |
|---|
Market Cap | 15M 80M |
|---|---|
Previous open | -2.93 |
Previous close | 1.78 |
News Sentiment
By Acuity
52%
48%
252 / 339 Healthcare
MediciNova Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
MediciNova Inc Forecast
Sentiment
By Acuity
252 / 339 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.